These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19232448)

  • 21. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia.
    Hayashi J; Furusyo N; Ariyama I; Sawayama Y; Etoh Y; Kashiwagi S
    J Infect Dis; 2000 May; 181(5):1523-7. PubMed ID: 10823749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
    Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of prognosis of small hepatocellular carcinoma patients with hepatitis B virus infection versus hepatitis C virus infection].
    Li HK; Qin Y; Li XM; Li Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):426-8. PubMed ID: 19567020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of hepatitis C virus infection to alcoholics with cirrhosis in Korea.
    Kwon SY; Ahn MS; Chang HJ
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1282-6. PubMed ID: 11129222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Soga K; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels.
    Ito T; Kumada T; Toyoda H; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S
    J Viral Hepat; 2015 Oct; 22(10):777-83. PubMed ID: 25608086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
    Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
    J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II.
    Yano Y; Yamashita F; Kuwaki K; Fukumori K; Kato O; Yamamoto H; Ando E; Tanaka M; Sata M
    Liver Int; 2006 Sep; 26(7):789-95. PubMed ID: 16911460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and associated risk factors of hepatocellular carcinoma in a dural hepatitis B and C virus endemic area: a surveillance study.
    Chang KC; Lu SN; Chen PF; Hung CH; Kee KM; Yen YH; Wang JH
    Kaohsiung J Med Sci; 2011 Mar; 27(3):85-90. PubMed ID: 21421195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.
    Mahmood S; Niiyama G; Kamei A; Izumi A; Nakata K; Ikeda H; Suehiro M; Kawanaka M; Togawa K; Yamada G
    Liver Int; 2005 Apr; 25(2):220-5. PubMed ID: 15780042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies.
    Tung HD; Wang JH; Tseng PL; Hung CH; Kee KM; Chen CH; Chang KC; Lee CM; Changchien CS; Chen YD; Lu SN
    Am J Gastroenterol; 2010 Mar; 105(3):624-31. PubMed ID: 20051944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.
    Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Sezaki H; Yatsuji H; Kawamura Y; Hosaka T; Kobayashi M; Arase Y; Ikeda K; Mineta R; Iwasaki S; Watahiki S; Miyakawa Y; Kumada H
    Scand J Gastroenterol; 2009; 44(8):975-83. PubMed ID: 19521923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma and hepatitis C in Mexico.
    Mondragón-Sánchez R; Garduño-López AL; Hernández-Castillo E; Gómez-Gómez E; Ruiz-Molina JM
    Hepatogastroenterology; 2005; 52(64):1159-62. PubMed ID: 16001652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase.
    Okanoue T; Makiyama A; Nakayama M; Sumida Y; Mitsuyoshi H; Nakajima T; Yasui K; Minami M; Itoh Y
    J Hepatol; 2005 Oct; 43(4):599-605. PubMed ID: 16024129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.
    Huo TI; Wu JC; Lee PC; Chau GY; Lui WY; Tsay SH; Ting LT; Chang FY; Lee SD
    Hepatology; 1998 Jul; 28(1):231-6. PubMed ID: 9657117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.